Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00260234|
Recruitment Status : Terminated (Stopped in December 2007)
First Posted : December 1, 2005
Last Update Posted : September 9, 2014
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 1||Biological: Allogeneic Cultured Islet Cells (human); Encapsulated||Phase 1 Phase 2|
Allogeneic Cultured Islet Cells (human, Novocell); Encapsulated in Polyethylene Glycol; Administered Subcutaneously are a combination biologic and device product in which the pharmacologically active agent is human insulin that is released from the functional islet cells by natural production and release, stimulated by control mechanisms in response to blood glucose concentrations. The device component is a uniform and conformal polymer coating around each islet. Islet cells are isolated from multiple human pancreases procured from human organ donors who meet a specific human donor profile established by the UNOS and the FDA's requirements for Good Tissue Practices. Because the pancreases used for islet cell isolation are not intended for whole-organ transplantation, specific procurement, surgical removal, packaging and shipping protocols are provided by Novocell, Inc. to the Organ Procurement Organizations.
The primary outcome is demonstration that encapsulated islet allografts can be implanted safely in the subcutaneous tissues without the use of long-term immunosuppression. The expected functional outcomes from the implantation of the encapsulated islets are significant reductions in the average blood glucose daily glycemic excursions and in insulin requirements as well as significant increases in C-peptide levels in response to meal challenges. The ultimate expected outcome is that patients who receive these implants will have reduced hemoglobin A1c levels that may be associated with reduced long-term diabetic complications. An important outcome should be reduction in hypoglycemic episodes and crises with significantly functioning grafts without having the risks associated with hepatic portal vein infusion and long-term immunosuppression.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Single-Center Phase I/II Study Of Peg-Encapsulated Islet Allografts Implanted In Patients With Type I Diabetes|
|Study Start Date :||November 2005|
|Actual Primary Completion Date :||December 2007|
|Actual Study Completion Date :||December 2007|
|Experimental: PEG Islet Cells||Biological: Allogeneic Cultured Islet Cells (human); Encapsulated|
- Safety - will be evaluated by the incidence, grade, and type of adverse events, changes in laboratory parameters, evaluation of the implant site and physical exams.
- Efficacy - will be assessed by:
- Blood glucose levels
- Daily glycemic excursions
- Pre-prandial glucose levels
- Post-prandial glucose levels
- Glucose responses from OGTT (mg/dL and AUC:glucose
- Stimulated C-peptide levels from OGTT (ng/mL and
- HbA1c (%)
- Insulin requirements (units/day)
- Arginine stimulation tests
- Numbers of hypoglycemic and hyperglycemic episodes
- Functional duration - will be determined by stimulated C-peptide from OGTT.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00260234
|United States, Texas|
|CHRISTUS Santa Rosa Transplant Institute|
|San Antonio, Texas, United States, 78229|
|Diabetes & Glandular Disease Research Associates, P.A.|
|San Antonio, Texas, United States, 78229|
|Principal Investigator:||Sherwyn Schwartz, M.D.||Diabetes & Glandular Disease Research Associates, P.A., San Antonio, TX|
|Principal Investigator:||Paraic Mulgrew, M.D.||CHRISTUS Santa Rosa Transplant Institute, San Antonio, TX|